14706014 Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist. - Evidence Based Medicine on FHIR Implementation Guide v2.0.0-ballot

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Example Citation: 14706014 Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist.

Active as of 2024-12-19

Generated Narrative: Citation 179628

version: 8; Last updated: 2024-11-22 19:14:41+0000

Profile: JournalArticleCitation

url: Citation 14706014 Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist.

identifier: FEvIR Object Identifier/https://fevir.net/FOI/179628, https://pubmed.ncbi.nlm.nih.gov/14706014, Uniform Resource Identifier (URI)/urn:oid:2.16.840.1.113883.4.642.40.44.15.16

version: 2.0.0-ballot

title: 14706014 Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist.

status: Active

date: 2024-12-19 14:29:51+0000

publisher: HL7 International / Clinical Decision Support

contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss

description:

This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.

UseContexts

Code

Value[x]

Citation Classification Type fevir-platform-use: FEvIR Platform Use

Medline Base

jurisdiction: World

copyright:

https://creativecommons.org/licenses/by-nc-sa/4.0/

approvalDate: 2004-06-15

lastReviewDate: 2019-09-22

author: Computable Publishing®: MEDLINE-to-FEvIR Converter:

classification
type: Citation Source
classifier: MEDLINE

classification
type: MEDLINE Citation Owner
classifier: National Library of Medicine, Index Section

currentState: Medline Citation Status of Medline, PubMed PublicationStatus of ppublish

statusDate
activity: PubMed Pubstatus of Pubmed
period: ?? --> 2004-01-07 05:00:00+0000

statusDate
activity: PubMed Pubstatus of Medline
period: ?? --> 2004-06-16 05:00:00+0000

statusDate
activity: PubMed Pubstatus of Entrez
period: ?? --> 2004-01-07 05:00:00+0000

citedArtifact
identifier: https://pubmed.ncbi.nlm.nih.gov/14706014, https://doi.org/10.1111/j.1442-2042.2004.t01-1-00748.x, pii/748
Titles
- Type Language Text
* Primary title English
Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist.

Abstracts
- Text
*
BACKGROUND: The present study was undertaken mainly to investigate whether chemohormonal therapy with estramustine phosphate plus luteinizing hormone-releasing hormone (LHRH) agonist has a more beneficial effect than the hormonal therapy with flutamide plus LHRH agonist for newly diagnosed patients with metastatic prostate cancer. METHODS: A total of 57 patients with metastatic prostate cancer aged 59-80 years (median 74 years) were entered in the study and were randomized to the treatment of estramustine phosphate (560 mg/day) plus LHRH agonist (estramustine group) or flutamide (375 mg/day) plus LHRH agonist (flutamide group) with stratification for the degree of performance status, histological differentiation and bone metastasis. RESULTS: Both of the treatment regimens were well tolerated with similar incidences of adverse drug reactions. The overall response rates (complete response plus partial response) at 12 weeks after treatment in the estramustine and flutamide groups were 76 and 55%, respectively. The median time to objective progression for the estramustine group (25.4 months) was longer than that of the flutamide group (14.6 months). The serum levels of follicle stimulating hormone and testosterone were significantly lower in the estramustine group. CONCLUSIONS: Chemohormonal therapy with estramustine phosphate plus LHRH agonist showed longer clinical progression-free survival than the hormonal therapy with flutamide plus LHRH agonist (P = 0.03), although there was no significant difference in the overall survival. A larger-scaled trial with more statistical power is required to clarify that the former regimen is more beneficial than the latter for newly diagnosed patients with advanced prostate cancer.

publicationForm
publishedIn
type: Periodical
identifier: Print ISSN Type/0919-8172, ISOAbbreviation/Int J Urol, ISSN Linking/0919-8172, Medline Title Abbreviation/Int J Urol, NLM Unique ID/9440237
title: International journal of urology : official journal of the Japanese Urological Association
publisherLocation: Australia
citedMedium: Print
volume: 11
issue: 2
articleDate: 2004-02
publicationDateText: 2004-Feb
language: English
pageString: 103-9
WebLocations
- Classifier Url
* Abstract https://pubmed.ncbi.nlm.nih.gov/14706014/
classification
type: Publishing Model
classifier: Print
classification
type: Chemical
classifier: Androgen Antagonists, Antineoplastic Agents, Hormonal, Gonadotropin-Releasing Hormone, Estramustine, Flutamide
classification
type: MeSH heading
artifactAssessment: ArtifactAssessment: artifact[x] = this resource
classification
type: Publication type
classifier: Clinical Trial, Journal Article, Randomized Controlled Trial
classification
type: Knowledge Artifact Type
classifier: Journal Article
artifactAssessment: Classifier added by Computable Publishing LLC
classification
type: Citation subset
classifier: IM
contributorship
complete: true
entry
contributor: Noguchi M
forenameInitials: M
affiliation: Department of Urology, Kurume University School of Medicine, Kurume, Japan. noguchi@med.kurume-u.ac.jp
entry
contributor: Noda S
forenameInitials: S
entry
contributor: Yoshida M
forenameInitials: M
entry
contributor: Ueda S
forenameInitials: S
entry
contributor: Shiraishi T
forenameInitials: T
entry
contributor: Itoh K
forenameInitials: K
entry
contributor: Kurume-Kumamoto Estracyt Study Group

Generated Narrative: Practitioner #contributor0

name: Masanori Noguchi

Generated Narrative: Practitioner #contributor1

name: Shinshi Noda

Generated Narrative: Practitioner #contributor2

name: Masaki Yoshida

Generated Narrative: Practitioner #contributor3

name: Shoichi Ueda

Generated Narrative: Practitioner #contributor4

name: Taizo Shiraishi

Generated Narrative: Practitioner #contributor5

name: Kyogo Itoh

Generated Narrative: Organization #contributor6

name: Kurume-Kumamoto Estracyt Study Group

Generated Narrative: ArtifactAssessment #meshHeading0

artifact: Citation 14706014 Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist.
content
type: components (if present) include qualifier codings
classifier: Aged
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Aged, 80 and over
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Androgen Antagonists
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: administration & dosage
Components
- Type Classifier
* is Major topic Yes
content
type: components (if present) include qualifier codings
classifier: Antineoplastic Agents, Hormonal
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: administration & dosage
Components
- Type Classifier
* is Major topic No
content
type: components (if present) include qualifier codings
classifier: Disease-Free Survival
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Dose-Response Relationship, Drug
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Drug Administration Schedule
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Drug Therapy, Combination
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Estramustine
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: administration & dosage
Components
- Type Classifier
* is Major topic Yes
content
type: components (if present) include qualifier codings
classifier: Flutamide
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: administration & dosage
Components
- Type Classifier
* is Major topic Yes
content
type: components (if present) include qualifier codings
classifier: Gonadotropin-Releasing Hormone
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: antagonists & inhibitors
Components
- Type Classifier
* is Major topic No
content
type: components (if present) include qualifier codings
classifier: Humans
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Male
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Middle Aged
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Neoplasm Invasiveness
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: pathology
Components
- Type Classifier
* is Major topic Yes
content
type: components (if present) include qualifier codings
classifier: Neoplasm Staging
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Probability
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Prognosis
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Prostatic Neoplasms
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: drug therapy
Components
- Type Classifier
* is Major topic Yes
component
type: qualifier
classifier: mortality
Components
- Type Classifier
* is Major topic No
component
type: qualifier
classifier: pathology
Components
- Type Classifier
* is Major topic Yes
content
type: components (if present) include qualifier codings
classifier: Survival Analysis
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Treatment Outcome
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic